Sienna Biopharmaceuticals (SNNA) Announces Quarterly Earnings Results, Misses Estimates By $0.10 EPS
Sienna Biopharmaceuticals (NASDAQ:SNNA) posted its quarterly earnings results on Thursday. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.10), MarketWatch Earnings reports.
SNNA opened at $2.54 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 4.86 and a current ratio of 4.86. Sienna Biopharmaceuticals has a 1 year low of $2.05 and a 1 year high of $21.53. The company has a market cap of $54.12 million, a P/E ratio of -0.49 and a beta of 3.66.
SNNA has been the topic of several recent research reports. Zacks Investment Research upgraded Sienna Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a research report on Wednesday, December 19th. ValuEngine lowered Sienna Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 24th. Cowen set a $45.00 price target on Sienna Biopharmaceuticals and gave the stock a “buy” rating in a research report on Monday, December 3rd. Finally, BMO Capital Markets reduced their price target on Sienna Biopharmaceuticals from $27.00 to $17.00 and set an “outperform” rating on the stock in a research report on Tuesday, December 4th.
COPYRIGHT VIOLATION NOTICE: This article was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://theolympiareport.com/2019/03/15/sienna-biopharmaceuticals-snna-issues-quarterly-earnings-results.html.
Sienna Biopharmaceuticals Company Profile
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
Recommended Story: What are retained earnings?
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.